Benzylacyclouridine enhances 5-fluorouracil cytotoxicity against human prostate cancer cell lines

Pharmacology

Volumn 56, Issue 2, 1998, Pages 80-91

  Yee, Lorrin K ^a,b   Chu, Edward ^b,c   Pan, Bai Chuan ^a   Chu, Shih Hsi ^a   Chen, Tian Min ^a   Lipsky, Michael H ^a   Chu, Ming Y W ^a   Calabresi, Paul ^a  

^a BROWN UNIVERSITY   (United States)

^b Department of Medicine ^*  (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

5 Fluorouracil; Benzylacyclouridine; Prostate cancer; Uridine phosphorylase

Indexed keywords

5 BENZYLACYCLOURIDINE; ANTINEOPLASTIC AGENT; DNA; ENZYME INHIBITOR; FLUOROPYRIMIDINE; FLUOROURACIL; RNA; THYMIDYLATE SYNTHASE; URIDINE PHOSPHORYLASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; METABOLITE; PRIORITY JOURNAL; PROSTATE CANCER; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FLUOROURACIL; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; URACIL; URIDINE PHOSPHORYLASE;

EID: 0031975545     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028185     Document Type: Article

References (42)

1. Parker SL,Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA 1997;47:5-27.
2. Oesteerling J, Fuks Z, Lee CT, Scher HL: Cancer of the prostate; in De Vita VT, Heliman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott-Raven, 1997, pp 1372-1386.
3. Eisenberger MA, Siimon R, O'Dwyer PJ, Wittes RE, Friedman MA: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827-841.
4. Eisenberger MA: Chemotherapy for endocrine resistant cancer of the prostate. Prog Clin Biol Res 1990; 359:155-164.
5. Eisenberger MA, Kennedy P, Abrams J: How effective is cytotoxic chemotherapy for disseminated prostate carcinoma? Oncology 1987; 1:59-71.
6. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
7. Kuzel TM, Tallman D, Shevrin D, Braud L, Kozlowski J, Vogelzang NJ, Blough MS, Benson AB 3d: A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer 1993;72:1965-1968.
8. Blumenstein B, Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA Jr: Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Group Study. J Urol 1993;150:411-413.
9. Wozniak AJ, Blumenstein BA, Crawford E, Boileau M, Rivkin SE, Fletcher WS: Cyclophophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group Study. Cancer 1993;71: 3975-3978.
10. Woodman PW, Arrif AM, Heidelberger C: Specificity of pyrimidine nucleoside phosphorylase and the phosphorylysis of 5-fluoro-2′-deoxyuridine. Cancer Res 1980;40:507-511.
11. Veres Z, Szboles A, Szinai I, Denes G, Jeney A: Enzymatic cleavage of the 5′-substituted 2′deoxyuridines by pyrimidine nucleoside phosphorylases. Biochem Pharmacol 1986; 35:1057-1059.
12. Birnie GD, Kroeger H, Heidelberger C: Studies of fluorinated pyrimidines. XVIII. The degradation of 5-fluoro-2′-deoxyuridine and related compounds by nucleoside phosphorylase. Biochemistry 1963;2:566-572.
13. LaCreta FP, Warren BS, Williams WM: Effects of pyrimidine nucleoside phosphorylase inhibitors on hepatic fluoropyrimidine elimination in the rat. Cancer Res 1992;49: 1729-1736.
14. Heidelberger C, Griesbach L, Cruz O, Schnitzer R, Grunberg E: Fluorinated pyrimidines. VI. Effects of fluorouridine and 5-fluoro-2′-deoxyuridine on transplanted tumors. Proc Soc Exp Biol Med 1958;97: 470.
15. 14 in cancer patients. Cancer Res 1963; 23:49.
16. Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW: High-dose 5-fluorouracil with delayed uridine 'rescue' in mice. Cancer Res 1982;42:3964-3970.
17. Chu MY, Naguib FNM, el Kouni MH, Cha S, Calabresi P: Potentiation of FdUrd antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine (BAU) and benzyloxybenzyl-acyclouridine (BBAU). Cancer Res 1984;44:1852-1856.
18. Darnowski JW, Handschumacher RE: Tissue specific enhancement of uridine utilization and 5-fluorouracil therapy in mice with benzylacyclouridine. Cancer Res 1985;45: 5364-5368.
19. Darnowski JW, Handschumacher RE: Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools. Pharmacol Ther 1983;41:381-392.
20. Chu SH, Wiemann MC, Chu MY, Calabresi P: Modulation of FUdR host toxicity by two benzylacyclouridineanalogs. Proc Am Assoc Cancer Res 1987;28:410.
21. Yee LK, Chu MYW, Lipsky MH, Chu SH, Chen TM, Calabresi P: Novel therapy for prostate cancer: Biochemical modulation of 5-fluorouracil (FUra) with the uridine phosphorylase inhibitor, benzylacyclouridine (BAU). Proc Am Assoc Cancer Res 1994;35:410.
22. Yee LK, Pan BC, Chu MYW, Chu E, Chu SH, Chen TM, Calabresi P: Benzylacyclouridine inhibits uridine phosphorylase activity and potentiates 5-fluorouracil cytotoxicity in human prostate cancer cell lines. Proc Am Assoc Cancer Res 1996;37: 409.
23. Niedzwicki JG, el Kouni MH, Chu SH, Cha S: Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases. Biochem Pharmacol 1983;32:399.
24. Chu E, Chu MY, Darnowski JW, Chen ZH, Pan BC, Chu SH: Enhancement of 5-fluoro-2′-deoxyuridine antineoplastic activity by 5 - benzyloxybenzyloxybenzylacyclouridine in a human colon carcinoma cell line. Cancer Res 1992;52:1729-1736.
25. Lipsky MH, Chu MY, Calabresi P, Chu SH, Forman EN: A rapid in vivo therapeutic assay for human carcinomas. Proc Am Assoc Cancer Res 1993;34:301.
26. Lipsky MH, Chu MY, Yee LK, Forman EN, Calabresi P: Predictive sensitivity of human cancer cells to anticancer agents in vivo. Proc Am Assoc Cancer Res 1994;35:373.
27. Tibbetts LN, Chu MY, Hager JC, Dexter DL, Calabresi P: Chemotherapy of cell-line derived human colon carcinoma in mice immunosuppressed with antithymocyte serum. Cancer 1977;40:2651-2659.
28. Chu MY, Zuckerman LB, Sato S, Crabtree GW, Bogden AE, Lim M-I, Klein RS: 9-Deazaadenosine: A new potent antitumor agent. Biochem Pharmacol 1984;33:1229-1234.
29. Chu MY, Fischer GA: Comparative studies of leukemic cells sensitive and resistant to cytosine arabinoside. Biochem Pharmacol 1965;14: 333-341.
30. 3H]cytosine arabinoside and the effect of murine leukemic cells (L5178Y). Biochem Pharmacol 1968;17:741-751.
31. Swain SM, Lippman ME, Egan EF, Drake JC, Stemberg SM, Allegra CJ: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:890-899.
32. Scholar EM, Calabresi P: Increased activity of alkaline phosphatase in leukemic cells from patients resistant to thiopurines. Biochem Pharmacol 1979;28:445-446.
33. Peters GJ, Laurensee A, Leyva A, Lankelma J, Pinedo HM: Sensitivity of Human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986; 46:20-28.
34. Bradford MM: A rapid and sensitive method for quantitatio of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
35. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH: In vivo kinetics of thymidyiate synthase inhibition in 5-fluorouracil sensitive and resistant murine colon adenocarcinomas. Cancer Res 1982; 42:450-456.
36. Keyomarsi K, Moran RG: Mechanism of the cytotoxic synergism of fluoropyrimidines and folic acid in mouse leukemic cells. J Biol Chem 1988;263:14402-14409.
37. Berne M, Gustavsson B, Almarsjo O, Spears CP, Waldenstrom J: Concurrent allopurinal and 5-fluoro-2′-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver. Cancer Chemother Pharmacol 1987;20:193-197.
38. Klubes P, Cerna I: Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Cancer Res 1983;43:3182-3186.
39. Monks A, Ayers O, Cysyk RL: Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the mechanism of circulating uridine by the isolated rat liver. Biochem Pharmacol 1983;32:2003-2009.
40. Peters GJ, Van Groeningen CL, Laurensee EJ, Leyva A, Pinedo HM: Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother Pharmacol 1987;20:101-108.
41. Darnowski JW, Handschumacher RE: Benzylacyclouridine pharmaco-kinetics, metabolism and biochemical effects in mice. Biochem Pharmacol 1988;37:2613-2618.
42. Martin DS, Stolfi RL, Sawyer RC: Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol 1989;24: 9-14.